TScan Pivots to In-Body T-Cell Therapy for Solid Tumors, Cuts 75% of Staff

TScan is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027.